Date: 2013-01-14
Type of information:
Compound: candidate drugs aimed at treating psychosis and other neuropsychiatric symptoms associated with major brain diseases such as Alzheimer’s disease and schizophrenia
Company: AstraZeneca (UK) Vanderbilt University (USA)
Therapeutic area: CNS diseases - Neurodegenerative diseases - Mental diseases - Psychiatric diseases
Type agreement: R&D
licensing
Action mechanism: These compounds are M4 Positive Allosteric Modulators (PAMs). They act on the M4 muscarinic acetylcholine receptor.
Disease: psychosis and other neuropsychiatric symptoms associated with major brain diseases such as Alzheimer’s disease and schizophrenia
Details: AstraZeneca and Vanderbilt University announced they have signed a research collaboration agreement to identify candidate drugs aimed at treating psychosis and other neuropsychiatric symptoms associated with major brain diseases such as Alzheimer’s disease and schizophrenia. Under the terms of the agreement, AstraZeneca has exclusively licensed rights to compounds developed by the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) that act on the M4 muscarinic acetylcholine receptor. These M4 Positive Allosteric Modulators (PAMs) were developed through Vanderbilt’s participation in the National Cooperative Drug Discovery and Development Group program supported by the National Institute of Mental Health.
Vanderbilt University and AstraZeneca will continue to collaborate to identify additional M4 compounds and further develop the existing compounds.
Financial terms: Vanderbilt will receive an upfront payment, research funding for two years as well as success-based milestones and royalties on global sales of products developed under the collaboration.
Latest news:
